Immune globulin intravenous Alternatives Compared
| Immune globulin intravenous | Ultomiris (ravulizumab) | Rystiggo (rozanolixizumab) |
|
|---|
| Immune globulin intravenous | Ultomiris (ravulizumab) | Rystiggo (rozanolixizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Chronic Lymphocytic Leukemia, Dermatomyositis, Primary Immunodeficiency Syndrome, Immune Thrombocytopenia, Anti NMDA Receptor... View more |
Prescription only
Prescribed for Myasthenia Gravis, Hemolytic Uremic Syndrome, Neuromyelitis Optica Spectrum Disorder, Paroxysmal Nocturnal Hemoglobinuria. Ultomiris may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Myasthenia Gravis. Rystiggo may also be used for purposes not listed in this medication guide. |
Related suggestions Myasthenia Gravis
Popular comparisons
|
|||||||||||||||
| More about Immune globulin intravenous | More about Ultomiris (ravulizumab) | More about Rystiggo (rozanolixizumab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Immune globulin intravenous has an average rating of 7.8 out of 10 from a total of 28 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 7% reported a negative effect. |
Ultomiris has an average rating of 9.5 out of 10 from a total of 8 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Rystiggo has an average rating of 8.0 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Ultomiris side effects |
View all Rystiggo side effects |
|||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ultomiris prices |
View all Rystiggo prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Alyglo, Asceniv, Bivigam, Carimune NF, Flebogamma, Gammagard S/D, Gammaplex, Octagam, Panzyga, Privigen, Yimmugo View more |
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
576 hours |
1192.8 hours |
N/A |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 106 drugs are known to interact with Immune globulin intravenous:
|
A total of 88 drugs are known to interact with Ultomiris:
|
A total of 298 drugs are known to interact with Rystiggo:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
December 21, 2018 |
June 26, 2023 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
|
||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Nplate
Nplate is used to prevent bleeding episodes in people with chronic immune thrombocytopenic purpura ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Imuran
Imuran is used for atopic dermatitis, autoimmune hepatitis, chronic active hepatitis, chronic ...
Hizentra
Hizentra (immune globulin) is used as a replacement therapy in patients with primary humoral ...
Privigen
Privigen is used to treat primary immune deficiency conditions and idiopathic thrombocytopenic ...
Gammagard Liquid
Gammagard (immune globulin) is used to treat primary immune deficiency and multifocal motor ...
Octagam
Octagam (immune globulin intravenous) is used to treat primary immunodeficiency diseases, immune ...
Vyvgart Hytrulo
Vyvgart Hytrulo is used to treat generalized myasthenia gravis (gMG) or chronic inflammatory ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.